Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4427)	8/8/2001 10:52:21 AM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Peter, Thank you very much. I was not aware of this article. I don't think it has been discussed at any of the "normal" places. The big question is of course what this means in general and for GZMO in particular. Does this cast a shadow over dendritic cell / cancer cell fusions as a concept, on the "German/Belgian" method using the electrofusion process or only on the specific trial(s) quoted in the article? As far as I am aware GZMO has not yet started any clinical trials using electrofusion. So far they have only used a chemical process. So, my take is that GZMO's exposure to this matter should be relatively limited, unless the whole concept of fusion vaccines falls to the ground. And even if it does GZMO do have a lot more in their bag. Lately they have started to talk "a lot" about using immunoconjugates against targets, which are unique to blood vessels feeding cancer tumors. That should compensate for whatever losses they might have on the electrofusion side. Ice